CorVel (NASDAQ:CRVL - Get Free Report) announced its quarterly earnings data on Tuesday. The business services provider reported $0.46 EPS for the quarter, Zacks reports. CorVel had a net margin of 9.64% and a return on equity of 31.73%.
CorVel Trading Down 5.6 %
Shares of CRVL traded down $6.83 on Friday, reaching $115.94. The company's stock had a trading volume of 87,987 shares, compared to its average volume of 106,891. CorVel has a twelve month low of $76.20 and a twelve month high of $128.61. The stock has a market capitalization of $5.91 billion, a PE ratio of 73.84 and a beta of 1.16. The firm has a fifty day moving average of $123.87 and a 200-day moving average of $112.35.
Wall Street Analysts Forecast Growth
Separately, StockNews.com lowered CorVel from a "buy" rating to a "hold" rating in a research report on Friday, January 3rd.
Read Our Latest Research Report on CorVel
Insider Activity
In other CorVel news, EVP Mark E. Bertels sold 1,050 shares of the company's stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $119.12, for a total value of $125,072.50. Following the completion of the transaction, the executive vice president now owns 2,580 shares in the company, valued at $307,321. This represents a 28.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 47.57% of the company's stock.
About CorVel
(
Get Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
See Also
Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
